Tackling Residual Atherosclerotic Risk in Statin-Treated Adults

Focus on Emerging Drugs

Kohei Takata, Stephen J. Nicholls

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Epidemiological studies and meta-analyses have consistently suggested the importance of lowering low-density lipoprotein cholesterol (LDL-C) to reduce cardiovascular (CV) events. However, these studies and mechanistic studies using intracoronary imaging modalities have reported patients who continue to experience CV events or disease progression despite optimal LDL-C levels on statins. These findings, including statin intolerance, have highlighted the importance of exploring additional potential therapeutic targets to reduce CV risk. Genomic insights have presented a number of additional novel targets in lipid metabolism. In particular, proprotein convertase subtilisin/kexin type 9 inhibitors have rapidly developed and recently demonstrated their beneficial impact on CV outcomes. Triglyceride (TG)-rich lipoproteins have been recently reported as a causal factor of atherosclerotic cardiovascular disease (ASCVD). Indeed, several promising TG-targeting therapies are being tested at various clinical stages. In this review, we present the evidence to support targeting atherogenic lipoproteins to target residual ASCVD risk in statin-treated patients.

Original languageEnglish
Pages (from-to)113-131
Number of pages19
JournalAmerican Journal of Cardiovascular Drugs
Volume19
Issue number2
DOIs
Publication statusPublished - 8 Apr 2019
Externally publishedYes

Cite this

@article{de19fed3d96f475ba3c8e7eff5d44192,
title = "Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs",
abstract = "Epidemiological studies and meta-analyses have consistently suggested the importance of lowering low-density lipoprotein cholesterol (LDL-C) to reduce cardiovascular (CV) events. However, these studies and mechanistic studies using intracoronary imaging modalities have reported patients who continue to experience CV events or disease progression despite optimal LDL-C levels on statins. These findings, including statin intolerance, have highlighted the importance of exploring additional potential therapeutic targets to reduce CV risk. Genomic insights have presented a number of additional novel targets in lipid metabolism. In particular, proprotein convertase subtilisin/kexin type 9 inhibitors have rapidly developed and recently demonstrated their beneficial impact on CV outcomes. Triglyceride (TG)-rich lipoproteins have been recently reported as a causal factor of atherosclerotic cardiovascular disease (ASCVD). Indeed, several promising TG-targeting therapies are being tested at various clinical stages. In this review, we present the evidence to support targeting atherogenic lipoproteins to target residual ASCVD risk in statin-treated patients.",
author = "Kohei Takata and Nicholls, {Stephen J.}",
year = "2019",
month = "4",
day = "8",
doi = "10.1007/s40256-018-0312-1",
language = "English",
volume = "19",
pages = "113--131",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Springer-Verlag London Ltd.",
number = "2",

}

Tackling Residual Atherosclerotic Risk in Statin-Treated Adults : Focus on Emerging Drugs. / Takata, Kohei; Nicholls, Stephen J.

In: American Journal of Cardiovascular Drugs, Vol. 19, No. 2, 08.04.2019, p. 113-131.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Tackling Residual Atherosclerotic Risk in Statin-Treated Adults

T2 - Focus on Emerging Drugs

AU - Takata, Kohei

AU - Nicholls, Stephen J.

PY - 2019/4/8

Y1 - 2019/4/8

N2 - Epidemiological studies and meta-analyses have consistently suggested the importance of lowering low-density lipoprotein cholesterol (LDL-C) to reduce cardiovascular (CV) events. However, these studies and mechanistic studies using intracoronary imaging modalities have reported patients who continue to experience CV events or disease progression despite optimal LDL-C levels on statins. These findings, including statin intolerance, have highlighted the importance of exploring additional potential therapeutic targets to reduce CV risk. Genomic insights have presented a number of additional novel targets in lipid metabolism. In particular, proprotein convertase subtilisin/kexin type 9 inhibitors have rapidly developed and recently demonstrated their beneficial impact on CV outcomes. Triglyceride (TG)-rich lipoproteins have been recently reported as a causal factor of atherosclerotic cardiovascular disease (ASCVD). Indeed, several promising TG-targeting therapies are being tested at various clinical stages. In this review, we present the evidence to support targeting atherogenic lipoproteins to target residual ASCVD risk in statin-treated patients.

AB - Epidemiological studies and meta-analyses have consistently suggested the importance of lowering low-density lipoprotein cholesterol (LDL-C) to reduce cardiovascular (CV) events. However, these studies and mechanistic studies using intracoronary imaging modalities have reported patients who continue to experience CV events or disease progression despite optimal LDL-C levels on statins. These findings, including statin intolerance, have highlighted the importance of exploring additional potential therapeutic targets to reduce CV risk. Genomic insights have presented a number of additional novel targets in lipid metabolism. In particular, proprotein convertase subtilisin/kexin type 9 inhibitors have rapidly developed and recently demonstrated their beneficial impact on CV outcomes. Triglyceride (TG)-rich lipoproteins have been recently reported as a causal factor of atherosclerotic cardiovascular disease (ASCVD). Indeed, several promising TG-targeting therapies are being tested at various clinical stages. In this review, we present the evidence to support targeting atherogenic lipoproteins to target residual ASCVD risk in statin-treated patients.

UR - http://www.scopus.com/inward/record.url?scp=85058849421&partnerID=8YFLogxK

U2 - 10.1007/s40256-018-0312-1

DO - 10.1007/s40256-018-0312-1

M3 - Review Article

VL - 19

SP - 113

EP - 131

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - 2

ER -